<DOC>
	<DOC>NCT02669433</DOC>
	<brief_summary>This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.</brief_summary>
	<brief_title>Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study</brief_title>
	<detailed_description>The efficacy and safety of RVT-101 at doses of 70 mg and 35 mg daily will be evaluated over a 24-week double-blind treatment period in patients with dementia with Lewy bodies. The randomization ratio will be 1:1:1 (70 mg RVT-101: 35 mg RVT-101: placebo). Subjects completing this study will be eligible to enroll in an extension study of RVT-101 (Study RVT-101-2002).</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Male or female subject with probable DLB Mini Mental State Examination (MMSE) score of 1426 inclusive at Screening and Baseline Patient has the ability to comply with procedures for cognitive and other testing in the opinion of the investigator Patient has a reliable caregiver who is willing to report on the subject's status throughout the study Patients currently receiving therapy for DLB are eligible for enrollment Atypical clinical features or clinical course that would lead the investigator to conclude primary symptoms are more likely explained by an alternate dementia diagnosis. Any clinically relevant concomitant disease that, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia with Lewy bodies</keyword>
	<keyword>Lewy bodies</keyword>
	<keyword>intepirdine</keyword>
	<keyword>RVT-101</keyword>
	<keyword>dementia</keyword>
</DOC>